Skip to main content

Why Pharma Companies Should File Clinical Trial-Related Patents Later In The R&D Process

As part of its Life Sciences special, IAM published an article authored by Member Alex Trimble discussing when in the research and development process pharma companies should file clinical trial-related patents. Alex explained that clinical trial-related patents should be filed later in the process and wrote, "This conservative filing strategy is unnecessary for the majority of clinical trial-related inventions, and reduces the value of the patent by prematurely starting the patent term clock. Instead, the better default timeframe for filing such an application is after the start of the Phase II clinical trials, as the delay does not increase the risk of invalidation for public use, but maximizes the exclusivity and value provided by the patent."

This article was originally published in IAM Magazine on March 31, 2023.



Download Article